Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Neurology
•
Neuro-immunology
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
Related Questions
What are your vaccine recommendations while patients are on biologics?
Is IVIG ever used to treat CNS neurosarcoidosis–related pain when the presentation is not consistent with peripheral neurosarcoid involvement?”
How does lack of success of rituximab treatment affect your decision to trial anti-CD19 therapies like inebilizumab?
What biomarkers best predict the response to B-cell depleting therapies in MS?
How do you decide when to discontinue immunotherapy for primary angiitis of the central nervous system (PACNS)?
How long would you continue chronic transfusion therapy for adult sickle cell patients who have had a stroke?
What do you recommend as a first-line antidepressant in patients with major depressive disorder and migraines?
Would you offer TPO-RAs to a steroid-refractory chronic ITP patient with history of stroke?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
In a patient with prior biopsy-proven IgG4-related pachymeningitis who develops recurrent neurologic symptoms years after discontinuing immunosuppression, how do you determine whether this represents relapse versus alternative etiologies?
